Literature DB >> 29506669

The Evolving Landscape of Brain Metastasis.

Manuel Valiente1, Manmeet S Ahluwalia2, Adrienne Boire3, Priscilla K Brastianos4, Sarah B Goldberg5, Eudocia Q Lee6, Emilie Le Rhun7, Matthias Preusser8, Frank Winkler9, Riccardo Soffietti10.   

Abstract

Metastasis, involving the spread of systemic cancer to the brain, results in neurologic disability and death. Current treatments are largely palliative in nature; improved therapeutic approaches represent an unmet clinical need. However, recent experimental and clinical advances challenge the bleak long-term outcome of this disease. Encompassing key recent findings in epidemiology, genetics, microenvironment, leptomeningeal disease, neurocognition, targeted therapy, immunotherapy, and prophylaxis, we review preclinical and clinical studies to provide a comprehensive picture of contemporary research and the management of secondary brain tumors.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  brain metastasis; genomics; microenvironment; neurocognition; prevention; therapy

Mesh:

Substances:

Year:  2018        PMID: 29506669      PMCID: PMC6602095          DOI: 10.1016/j.trecan.2018.01.003

Source DB:  PubMed          Journal:  Trends Cancer        ISSN: 2405-8025


  57 in total

Review 1.  Metastasis Organotropism: Redefining the Congenial Soil.

Authors:  Yang Gao; Igor Bado; Hai Wang; Weijie Zhang; Jeffrey M Rosen; Xiang H-F Zhang
Journal:  Dev Cell       Date:  2019-05-06       Impact factor: 12.270

2.  Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.

Authors:  Sarah B Goldberg; Kurt A Schalper; Scott N Gettinger; Amit Mahajan; Roy S Herbst; Anne C Chiang; Rogerio Lilenbaum; Frederick H Wilson; Sacit Bulent Omay; James B Yu; Lucia Jilaveanu; Thuy Tran; Kira Pavlik; Elin Rowen; Heather Gerrish; Annette Komlo; Richa Gupta; Hailey Wyatt; Matthew Ribeiro; Yuval Kluger; Geyu Zhou; Wei Wei; Veronica L Chiang; Harriet M Kluger
Journal:  Lancet Oncol       Date:  2020-04-03       Impact factor: 41.316

3.  Targeting an adhesion molecule to prevent brain colonization of lung cancer.

Authors:  Matthia A Karreman; Frank Winkler
Journal:  Neuro Oncol       Date:  2020-07-07       Impact factor: 12.300

Review 4.  The blood-brain barrier and blood-tumour barrier in brain tumours and metastases.

Authors:  Costas D Arvanitis; Gino B Ferraro; Rakesh K Jain
Journal:  Nat Rev Cancer       Date:  2019-10-10       Impact factor: 60.716

5.  Type and timing of systemic therapy use predict overall survival for patients with brain metastases treated with radiation therapy.

Authors:  Kevin Yijun Fan; Nafisha Lalani; Nathalie LeVasseur; Andra Krauze; Fred Hsu; Lovedeep Gondara; Kaylie Willemsma; Alan McVey Nichol
Journal:  J Neurooncol       Date:  2020-11-18       Impact factor: 4.130

Review 6.  The blood-tumour barrier in cancer biology and therapy.

Authors:  Patricia S Steeg
Journal:  Nat Rev Clin Oncol       Date:  2021-07-12       Impact factor: 66.675

7.  Breast brain metastases are associated with increased risk of leptomeningeal disease after stereotactic radiosurgery: a systematic review and meta-analysis.

Authors:  Desmond A Brown; Victor M Lu; Benjamin T Himes; Terry C Burns; Alfredo Quiñones-Hinojosa; Kaisorn L Chaichana; Ian F Parney
Journal:  Clin Exp Metastasis       Date:  2020-01-16       Impact factor: 5.150

8.  A TAZ-AXL-ABL2 Feed-Forward Signaling Axis Promotes Lung Adenocarcinoma Brain Metastasis.

Authors:  Jacob P Hoj; Benjamin Mayro; Ann Marie Pendergast
Journal:  Cell Rep       Date:  2019-12-10       Impact factor: 9.423

Review 9.  A view on drug resistance in cancer.

Authors:  José Baselga; David M Hyman; Neil Vasan
Journal:  Nature       Date:  2019-11-13       Impact factor: 49.962

10.  Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging.

Authors:  Jennifer A Geisler; Jonathan M Spehar; Sarah A Steck; Anna Bratasz; Reena Shakya; Kimerly Powell; Gina M Sizemore
Journal:  J Vis Exp       Date:  2020-06-07       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.